Tarsus Pharmaceuticals delivered its strongest quarter to date, with net product sales exceeding $100 million, primarily due to the continued success and rapid adoption of XDEMVY. The company significantly reduced its net loss compared to the prior year, demonstrating strong commercial execution and pipeline advancements.

Tarsus Pharmaceuticals reported strong performance in Q1 2025, driven by robust net product sales of XDEMVY, which increased 217% year over year. The company also strengthened its financial position with a successful equity offering and advanced its pipeline, including plans to initiate a Phase 2 trial for TP-04.

Tarsus Pharmaceuticals reported positive Q4 2024 financial results, highlighted by net product sales of XDEMVY reaching $66.4 million. The company continued to advance its pipeline, including TP-04 for Ocular Rosacea and TP-05 for Lyme disease prevention. Broad reimbursement coverage for XDEMVY was established, and a direct-to-consumer campaign was launched.

Tarsus Pharmaceuticals reported a successful third quarter, marked by significant growth in XDEMVY net product sales, driven by increased patient reach and strong payer coverage. The company also presented new clinical data and expanded its leadership team.

Tarsus Pharmaceuticals reported a strong second quarter in 2024, marked by a 65% increase in revenue compared to Q1 2024, driven by $40.8 million in XDEMVY net product sales. The company saw an improved gross-to-net discount of 44% and delivered over 37,000 bottles of XDEMVY to patients. However, the net loss was $33.3 million, impacted by increased selling, general, and administrative expenses related to the commercial launch of XDEMVY.

Tarsus Pharmaceuticals reported strong first-quarter results, driven by significant growth in XDEMVY sales. The company is focused on expanding payer coverage and sales force to further accelerate its launch trajectory.

Tarsus Pharmaceuticals reported strong Q4 2023 financial results, driven by $13.1 million in revenues from XDEMVY net product sales. The company also highlighted the positive progress of its clinical pipeline and commercial initiatives.

Tarsus Pharmaceuticals announced its Q3 2023 financial results, highlighting the successful launch of XDEMVY® which generated $1.7 million in net product sales. The company's total revenues reached $1.9 million. Despite increased R&D and SG&A expenses, Tarsus ended the quarter with a strong cash position of $246.9 million.

Tarsus Pharmaceuticals reported a net loss of $31.4 million for the second quarter of 2023, compared to a net loss of $5.7 million for the same period in 2022. The company achieved FDA approval for XDEMVY for Demodex blepharitis and completed enrollment in a Phase 2a trial for Rosacea.

Tarsus Pharmaceuticals reported a net loss of $23.4 million for the first quarter of 2023. License fee and collaboration revenue was $2.5 million, while research and development expenses were $12.4 million, and general and administrative expenses were $15.1 million. Cash, cash equivalents and marketable securities totaled $201.2 million as of March 31, 2023.

Tarsus Pharmaceuticals reported full-year 2022 financial results, including TP-03 out-license revenue for greater China territory of $25.8 million and a net loss of $62.1 million. The company highlighted the acceptance of the NDA for TP-03 for Demodex blepharitis by the FDA with a PDUFA target action date of August 25, 2023, and the advancement of its pipeline with Phase 2 trials in rosacea and planned Phase 2a data readouts.

Tarsus Pharmaceuticals reported a net loss of $22.5 million for the third quarter of 2022. The New Drug Application for TP-03 was accepted, with a target action date of August 25, 2023. The company's cash runway is anticipated into at least 2026.

Tarsus Pharmaceuticals reported a net loss of $5.7 million for the second quarter of 2022. License fee and collaboration revenue was $15.3 million, and cash and cash equivalents were $245.4 million as of June 30, 2022. The company is advancing TP-03 for Demodex blepharitis and expanding its commercial team.

Tarsus Pharmaceuticals reported a net loss of $20.2 million for the first quarter of 2022, compared to a net income of $10.4 million for the same period in 2021. The company's TP-03 product met all endpoints in the Saturn-2 Phase 3 trial, and the company anticipates NDA submission in the second half of this year. Cash runway is expected into at least 2026.

Tarsus Pharmaceuticals reported a full-year net loss of $13.8 million, with research and development expenses at $41.7 million and general and administrative expenses at $25.4 million. The company's cash, cash equivalents, and marketable securities totaled $171.8 million as of December 31, 2021. They anticipate topline data for the Saturn-2 Phase 3 trial in April 2022 and an NDA submission this year for TP-03.

Tarsus Pharmaceuticals reported a net loss of $15.7 million for the third quarter of 2021. The company is on track to complete enrollment in the Saturn-2 Phase 3 trial for TP-03 by the end of the year and expects topline data in Q1 2022. They also continue to advance the Callisto Phase 1 trial of TP-05.

Tarsus Pharmaceuticals announced positive results from the Saturn-1 pivotal trial for TP-03, initiated the Saturn-2 and Callisto trials, and reported a net income of $6.3 million for the second quarter of 2021, compared to a net loss of $(3.3) million for the same period in 2020.

Tarsus Pharmaceuticals reported a net income of $10.4 million for the first quarter of 2021, a significant increase compared to the net loss of $(2.0) million for the same period in 2020. The company's cash and cash equivalents totaled $156.2 million as of March 31, 2021.

Tarsus Pharmaceuticals reported a net loss of $26.8 million for the full year 2020. The company's cash and cash equivalents stood at $168.1 million as of December 31, 2020. A strategic partnership with LianBio was established in March 2021 for TP-03 in Greater China, providing Tarsus with $70 million expected during the next 12 months and up to $130 million in future milestones, plus double-digit royalties and equity in LianBio.